Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cellebrite DI (CLBT) Operating Expenses (2020 - 2025)

Cellebrite DI's Operating Expenses history spans 6 years, with the latest figure at $88.3 million for Q4 2025.

  • Quarterly Operating Expenses rose 16.68% to $88.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $334.0 million through Dec 2025, up 18.57% year-over-year, with the annual reading at $334.0 million for FY2025, 18.57% up from the prior year.
  • Operating Expenses came in at $88.3 million for Q4 2025, up from $86.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $88.3 million in Q4 2025 to a low of $40.7 million in Q1 2021.
  • The 5-year median for Operating Expenses is $58.9 million (2023), against an average of $63.2 million.
  • Year-over-year, Operating Expenses skyrocketed 64.07% in 2021 and then fell 0.69% in 2023.
  • Cellebrite DI's Operating Expenses stood at $51.3 million in 2021, then grew by 1.85% to $52.2 million in 2022, then grew by 20.85% to $63.1 million in 2023, then grew by 19.97% to $75.7 million in 2024, then rose by 16.68% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Operating Expenses are $88.3 million (Q4 2025), $86.7 million (Q3 2025), and $81.2 million (Q2 2025).